Association of Ledipasvir-Sofosbuvir Treatment With Uveitis in Patients Treated for Hepatitis C
| Autor: | Jonathan K. Hu, Xihui Lin, Marie T. Burke, Sneha Padidam, Daniel Apple |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
medicine.medical_specialty Time Factors Visual acuity genetic structures Fundus Oculi Optic Disk Visual Acuity Antiviral Agents Severity of Illness Index 01 natural sciences Retina 03 medical and health sciences 0302 clinical medicine Blurred vision Ophthalmology medicine Humans Fluorescein Angiography 0101 mathematics Macular edema Aged Hepatitis Fluorenes business.industry Brief Report 010102 general mathematics Uveitis Posterior Hepatitis C Hepatitis C Chronic Middle Aged medicine.disease eye diseases 030221 ophthalmology & optometry Benzimidazoles Female Sofosbuvir medicine.symptom Uridine Monophosphate business Vasculitis Tomography Optical Coherence Uveitis Follow-Up Studies Retinopathy |
| Zdroj: | JAMA Ophthalmology. 137:568 |
| ISSN: | 2168-6165 |
| Popis: | Importance Ledipasvir-sofosbuvir has become the current standard of care for hepatitis C since its release in 2014. Therefore, potential adverse effects are important to identify. Objective To report findings of uveitis after treatment with ledipasvir-sofosbuvir for hepatitis C. Design, setting, and participants This case series includes patients treated in an urban academic setting with ledipasvir-sofosbuvir for hepatitis C from June 2015 to June 2017 who are known to have developed signs and symptoms of posterior uveitis. Exposures All patients had been treated with ledipasvir-sofosbuvir for hepatitis C for a total of 12 weeks. All patients but 1 had finished treatment prior to presentation. Main outcomes and measures Signs of posterior uveitis on ophthalmic testing. Results Data were collected from 6 patients (median age, 64.5 [range, 54-72] years). Five patients were male; 4 were white, and 2 were African American. The mean (SD) time between beginning of treatment and presentation was 8.8 (5.5) months. Both eyes were affected in 3 of the 6 patients (total, 9 eyes). The median presenting visual acuity in affected eyes was 20/40 (range, 20/20-20/70). All patients had a negative systemic uveitis workup. Five patients presented with blurred vision, and 1 had a paracentral scotoma. The main ocular findings were peripheral vasculitis (in 8 of 9 eyes), papillitis (in 7 of 9 eyes), and cystoid macular edema (in 6 of 9 eyes). The median follow-up was 8 (range, 4-13) months. The median final visual acuity was 20/40 (range, 20/20-20/200). Conclusions and relevance In these patients, it appears that treatment with ledipasvir-sofosbuvir for hepatitis C was associated with a mild posterior uveitis different than interferon retinopathy. Given the large number of patients treated with ledipasvir-sofosbuvir, these findings cannot be considered causative, and an association cannot be quantified at this time. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|